Tüdőrák: vizsgálatok itt: Argentína

In Argentína 47 Also abroad 2746

47 trials · From ClinicalTrials.gov, checked 2026. november 14.. Ask the study team whether a trial fits you.

3. fázisVisszavonva
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Buenos Aires, Córdoba, TBC, Viedma
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Buenos Aires, Ciudad Autónoma de Buenos Aires, Río Cuarto, Rosario
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Buenos Aires, Córdoba, La Rioja, San Miguel de Tucumán, Viedma
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
CABA, Ciudad Autónoma de Bs As
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
2/3. fázisTaking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Belgrano, Buenos Aires, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Pergamino, Porto Alegre, Río Cuarto, Rosario, San Pedro, Viedma
Életkor
18 év and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
3. fázisTaking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Buenos Aires, Ciudad Autonoma Buenos Aires, Ciudad Autonoma de Buenos Aire, Viedma
Életkor
18 év and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
3. fázisTaking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Bariloche, Buenos Aires, Ciudad Autónoma de Buenos Aires, Mar del Plata, Río Cuarto, Rosario
Életkor
18 év and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Buenos Aires, CABA, La Plata, Pilar, Rosario
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Buenos Aires, CABA, La Plata, Pilar, Rosario
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
1/2. fázisTaking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Buenos Aires, Ciudad Autonoma de Buenos Aire
Életkor
18 év and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
3. fázisTaking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
ABB, CABA, Ciudad Autónoma de Buenos Aires, Ciudad de Buenos Aires, Pilar, Rosario
Életkor
18 év and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
3. fázisTaking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Buenos Aires, Ciudad Autonoma Buenos Aires, Córdoba, Pergamino, Pilar, Rosario, San Juan
Életkor
18 év and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
3. fázisTaking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Buenos Aires, Córdoba, Mar del Plata, Rosario, San Miguel de Tucumán
Életkor
18 év and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
2. fázisTaking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Buenos Aires, Rosario, Viedma
Életkor
18 év and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
3. fázisTaking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Buenos Aires, San Juan, San Miguel de Tucumán, Santa Fe
Életkor
18 év and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
3. fázisNot yet taking people in Argentína
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Ciudad Autónoma de Buenos Aires, Córdoba, Pergamino, Pilar
Életkor
18 év and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
3. fázisTaking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Buenos Aires, CABA, Ciudad Autónoma de Buenos Aires, Córdoba, Florida, La Rioja, Mar del Plata, Mendoza, Pergamino, Pilar
Életkor
18 év and over
People
1410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
1/2. fázisTaking people
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Where
Pilar, Rosario
Életkor
18 év and over
People
327 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00
3. fázisTaking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Córdoba, Rosario
Életkor
18 év and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
CABA, Córdoba, Pilar, Rosario, Viedma
Életkor
18 év and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
No phaseTaking people
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Where
Buenos Aires
Életkor
18 év and over
People
200 worldwide
Run by
Latin American Cooperative Oncology Group
See details and how to joinNCT07192991
No phaseFut, nem toboroz
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Where
Rosario
Életkor
40 év to 75 év
People
6000 worldwide
Run by
Javier Toledo
See details and how to joinNCT06717295